Semaglutide + B6
Compounded semaglutide with vitamin B6 (pyridoxine) as a sterile injectable. A GLP-1 receptor agonist used with diet and activity for weight and glucose support.12 Including B6 with semaglutide may reduce nausea for some patients compared to semaglutide alone.34
Compounding required for medical necessity.
- Active ingredients
- Semaglutide
- Form
- Injection
- Route
- Subcutaneous
Are you a prescriber?
Download a compounding order form for this medication with dose options and packaging choices.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In the STEP 1 trial of the branded molecule, once-weekly semaglutide plus lifestyle intervention produced sustained, clinically relevant weight loss versus placebo in adults with overweight or obesity.1
U.S. prescribing information for approved semaglutide products describes use with a reduced-calorie diet and increased physical activity, and includes a boxed warning about thyroid C-cell tumors observed in rodents.2
This preparation includes pyridoxine hydrochloride (vitamin B6) as an additive. Vitamin B6 is being studied for nausea support in other clinical settings, including randomized and pooled pregnancy data.34 That research does not establish that adding B6 makes this compounded product more effective than semaglutide alone, or that it prevents GLP-1-related stomach side effects.
Connect Wellness compounds this sterile injectable for patient-specific prescriptions when a compounded formulation is medically necessary. It is not an FDA-approved finished drug product. Your clinician determines dose titration and monitoring. Common class-related effects include gastrointestinal symptoms and reduced appetite. Review personal or family history of medullary thyroid carcinoma or MEN2 and other contraindications before use.
References
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002
“In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”
- U.S. Food and Drug Administration (2025). WEGOVY (semaglutide) injection, for subcutaneous use — Prescribing Information. FDA Prescribing Information
- Sahakian V et al. (1991). Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstetrics & Gynecology, 78, 33-36
- Jayawardena R et al. (2023). The effects of pyridoxine (vitamin B6) supplementation in nausea and vomiting during pregnancy: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 308, 1075-1084